Company Description
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.
The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines.
It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program.
Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies.
Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health – Abu Dhabi for the development of global vaccines.
The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
| Country | France |
| Founded | 1994 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 82,878 |
| CEO | Paul Hudson |
Contact Details
Address: 46, avenue de la Grande Armée Paris, 75017 France | |
| Phone | 33 1 53 77 40 00 |
| Website | sanofi.com |
Stock Details
| Ticker Symbol | SNY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001121404 |
| CUSIP Number | 80105N105 |
| ISIN Number | US80105N1054 |
| Employer ID | 13-3529324 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Hudson | Chief Executive Officer and Director |
| François-Xavier Roger | Executive Vice President and Chief Financial Officer |
| Madeleine Roach | Executive Vice President and Head of Business Operations |
| Thomas Kudsk Larsen | Head of Investor Relations |
| Roy Papatheodorou | Executive Vice President and General Counsel |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing |
| Natalie Bickford | Executive Vice President and Chief People Officer |
| Olivier Charmeil | Executive Vice President of General Medicines |
| Fabrizio Gaudi | Head of Austrian, German and Swiss Operations |
| Felix Lauscher | Head of IR North America and Asia |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | SCHEDULE 13G/A | Filing |
| Aug 7, 2025 | 6-K | Report of foreign issuer |
| Jul 31, 2025 | 6-K | Report of foreign issuer |
| Jul 31, 2025 | 6-K | Report of foreign issuer |
| Jul 31, 2025 | 6-K | Report of foreign issuer |
| Jul 30, 2025 | N-PX | Annual Report of proxy voting record of management investment companies |
| Jul 29, 2025 | 13F-HR | Quarterly report filed by institutional managers, holdings |
| Jul 22, 2025 | 6-K | Report of foreign issuer |
| Jul 18, 2025 | 6-K | Report of foreign issuer |
| Jul 2, 2025 | 6-K | Report of foreign issuer |